Lee Golden
Net worth: 6 M $ as of 30/05/2026
Net worth: 6 M $ as of 30/05/2026
Dr. Lee S.
Golden, MD, is an Independent Director at Cadrenal Therapeutics, Inc. and a Chief Medical Officer & Executive Vice President at PTC Therapeutics, Inc. He is on the Board of Directors at Cadrenal Therapeutics, Inc. Dr. Golden was previously employed as a Chief Medical Officer by Espero Pharmaceuticals, Inc., a Chief Medical Officer by Gemphire Therapeutics, Inc., a Head-Pulmonary by Mesoblast Ltd., a Head-Cardiovascular & Blood Disorders by Eisai, Inc., a Senior Director-US Medical by Actelion Pharmaceuticals US, Inc., and a Medical Director by Pfizer Inc. He also served on the board at Coagulation Sciences LLC.
He received his undergraduate degree from the University of Michigan and a doctorate degree from New York University School of Medicine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 09/04/2026 | 79,964 ( 0.1% ) | 6 M $ | 30/05/2026 | |
| 01/12/2025 | 1,667 ( 0.06% ) | 8 268 $ | 30/05/2026 |
| Companies | Position | Start |
|---|---|---|
| PTC THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31/12/2021 |
| CADRENAL THERAPEUTICS, INC. | Director/Board Member | 23/11/2025 |
| Companies | Position | End |
|---|---|---|
Espero Pharmaceuticals, Inc.
Espero Pharmaceuticals, Inc. Medical DistributorsDistribution Services Manufactures and supplies drugs related to cardiovascular | Chief Tech/Sci/R&D Officer | 30/04/2020 |
| METAVIA INC. | Chief Tech/Sci/R&D Officer | 17/09/2018 |
| MESOBLAST LIMITED | Corporate Officer/Principal | 30/09/2016 |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers pharmaceutical products | Corporate Officer/Principal | 30/06/2011 |
Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Manufactures, distributes and markets drugs | Corporate Officer/Principal | 29/02/2008 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 11 |
|---|---|
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
PTC Therapeutics, Inc.
PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Manufacturers pharmaceutical products | Health Technology |
University of Michigan
University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mesoblast Ltd.
Mesoblast Ltd. BiotechnologyHealth Technology Engages in the development and commercialization of biological and adult stem cells products | Health Technology |
Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Manufactures, distributes and markets drugs | Health Technology |
New York University School of Medicine
New York University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Coagulation Sciences LLC
Coagulation Sciences LLC Medical/Nursing ServicesHealth Services Provides blood-testing solutions | Health Services |
Gemphire Therapeutics, Inc.
Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies for the treatment of Dyslipidemia | Health Technology |
Espero Pharmaceuticals, Inc.
Espero Pharmaceuticals, Inc. Medical DistributorsDistribution Services Manufactures and supplies drugs related to cardiovascular | Distribution Services |
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel therapy with orphan drug indication | Health Technology |
Select your edition
All financial news and data tailored to specific country editions